Sihuan Pharmaceutical Holdings Group (0460) AI Stock Analysis

• Market Cap: $12.13B
• Dividend Yield: 1.62%
• Average Volume (3M): 99.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: -0.11%
• EPS Growth: -290.77%
• Country: HK
• Employees: 2,667
• Sector: Healthcare
• Sector Strength: 38
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 9,329,999,000
• 10 Day Avg. Volume: 79,559,125
• 30 Day Avg. Volume: 99,639,827
• PEG Ratio: 0.11
• Price to Book (P/B): 2.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -980.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: HK$1.50 ▲(15.38%Upside)

Sihuan Pharmaceutical's overall stock score is primarily influenced by its financial challenges, including declining revenues and profitability issues. Technical analysis shows positive momentum, but overbought conditions suggest caution. Valuation metrics indicate the stock is overvalued with limited income potential, further impacting the score.

Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model

Company Description

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.

How the Company Makes Money

Sihuan Pharmaceutical Holdings Group generates revenue through the sale of its pharmaceutical products, which include both proprietary drugs and generic medicines. The company's key revenue streams are derived from its cardiovascular, metabolism, oncology, and anti-infective product lines. Sihuan Pharmaceutical also leverages strategic partnerships and collaborations with other pharmaceutical and biotechnology firms to enhance its research and development efforts. Additionally, the company benefits from its extensive distribution network, which ensures the availability of its products across various regions. Government policies and healthcare reforms in China can significantly impact the company's earnings by influencing drug pricing and market access.

Sihuan Pharmaceutical Holdings Group Financial Statement Overview

Summary

Sihuan Pharmaceutical's financial performance is under pressure, with declining revenue and consistent net losses. The balance sheet shows a stable asset base but declining equity, and cash flow analysis indicates potential liquidity issues.

Income Statement

Sihuan Pharmaceutical's income statement reflects significant challenges in recent years. The company experienced a substantial decline in revenue from 2021 to 2024, with revenue decreasing from approximately 3.04 billion to 1.90 billion. Gross profit margins have remained relatively stable, but consistent net losses have been reported, indicating profitability issues. The EBIT and EBITDA margins have turned negative, suggesting operational inefficiencies and a need for cost management improvements.

Balance Sheet

The balance sheet indicates a mixed financial position. The company's debt-to-equity ratio is low, which is positive, but stockholders' equity has decreased over time. The equity ratio remains adequate, reflecting a stable asset base. However, the decline in total assets and stockholders' equity raises concerns about long-term financial stability.

Cash Flow

Cash flow analysis shows significant volatility. The company's free cash flow has fluctuated, with recent years showing negative free cash flow, indicating potential liquidity issues. Operating cash flow has also been inconsistent, with the most recent period showing zero, highlighting challenges in generating cash from operations. These factors suggest a need for improved cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.90B	1.86B	2.18B	3.04B	2.46B
Gross Profit	1.24B	1.30B	1.49B	2.43B	1.91B
EBITDA	-208.66M	334.31M	-1.54B	931.69M	714.06M
Net Income	-216.66M	-54.02M	-1.95B	416.51M	473.38M
Balance Sheet
Total Assets	10.53B	11.54B	12.14B	14.50B	13.04B
Cash, Cash Equivalents and Short-Term Investments	3.63B	4.37B	4.79B	5.79B	4.94B
Total Debt	942.76M	1.26B	1.19B	1.08B	755.05M
Total Liabilities	5.58B	6.40B	6.50B	5.35B	3.10B
Stockholders Equity	4.37B	4.43B	4.74B	8.28B	9.19B
Cash Flow
Free Cash Flow	57.51M	-95.93M	-355.97M	64.28M	-279.51M
Operating Cash Flow	243.89M	199.49M	46.49M	665.29M	227.13M
Investing Cash Flow	758.24M	169.88M	-1.66B	-337.57M	-924.78M
Financing Cash Flow	-1.26B	-419.56M	-238.93M	750.66M	184.54M

Sihuan Pharmaceutical Holdings Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Positive. The current price of 1.3 is below the 20-day moving average (MA) of 1.30, above the 50-day MA of 1.16, and above the 200-day MA of 0.78, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 55.40 is Neutral, neither overbought nor oversold. The STOCH value of 11.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0460.

Sihuan Pharmaceutical Holdings Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.35B	0.50	-65.61%	2.47%	15.28%	1.44%
0460	49 Neutral	$12.13B	―	-4.93%	1.62%	-0.11%	-290.77%
CHIZF	―	$1.44B	183.33	0.25%	3.92%	―	―
C1P	―	€1.23B	9.41	23.28%	5.08%	―	―
0719	70 Outperform	HK$10.69B	11.58	8.89%	3.55%	4.91%	-11.80%
1558	65 Neutral	HK$12.65B	26.73	5.88%	10.31%	-42.02%	-76.29%
6185	57 Neutral	HK$13.73B	―	-4.41%	―	94.98%	85.69%

Sihuan Pharmaceutical Holdings Group Corporate Events

Sihuan Pharmaceutical Projects Strong Revenue and Profit Growth for 2025

Sihuan Pharmaceutical Holdings Group Ltd. has announced a positive profit alert, expecting to achieve a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the first half of 2025. This growth is driven by a significant increase in the medical aesthetics business, the successful commercialization of new innovative drugs, and a narrowing decline in the generic drug sector. The company has received approvals for 41 new products, which are anticipated to boost future revenue and profit growth.

Sihuan Pharmaceutical Advances Phase III Trial for Innovative Drug Anaprazole Sodium

Sihuan Pharmaceutical Holdings Group has announced the completion of the first patient enrollment in a Phase III clinical trial for Anaprazole Sodium Enteric Coated Tablets, targeting reflux esophagitis. This development marks an expansion of indications for the drug, which is the first and only fully independently developed proton pump inhibitor (PPI) in China. The trial, involving multiple leading medical institutions, aims to evaluate the drug’s efficacy and safety, potentially broadening its market reach and creating commercial synergies. The growing prevalence of reflux esophagitis and peptic ulcers in China, combined with the drug’s unique properties, positions it for significant clinical and commercial success.

Sihuan Pharmaceutical Acquires 10 Million Shares Under Award Scheme

Sihuan Pharmaceutical Holdings Group Ltd. announced a voluntary share purchase under its 2022 Share Award Scheme, acquiring 10,000,000 shares, which represents approximately 0.11% of the total shares issued. This move is part of the company’s strategic efforts to enhance its market position and incentivize its stakeholders, reflecting its commitment to growth and leadership in the pharmaceutical and medical aesthetic industries.

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan Amidst Strong Product Launches

Sihuan Pharmaceutical Holdings Group Ltd. has announced a share repurchase plan of up to HK$500 million, with a recent repurchase of 20 million shares at an average price of HK$1.0910 per share. This move is part of the company’s strategy to enhance shareholder value and reflects confidence in its growth prospects. The company has made significant strides in its medical aesthetics and innovative pharmaceuticals sectors, with substantial revenue growth and the launch of numerous new products. This expansion is expected to drive future revenue and profit growth, reinforcing Sihuan Pharmaceutical’s position in the industry.

Sihuan Pharmaceutical’s New Breast Cancer Treatment Gains Regulatory Acceptance

Sihuan Pharmaceutical Holdings Group announced that their New Drug Application for a new indication of Bireociclib Tablets, in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer, has been accepted by China’s National Medical Products Administration. This development highlights the company’s strong R&D capabilities and positions them to provide comprehensive treatment options for breast cancer patients, addressing a significant demand in the global market for CDK4/6 inhibitors, which is projected to grow substantially.

Sihuan Pharmaceutical Approves Key Resolutions at AGM

Sihuan Pharmaceutical Holdings Group Ltd. held its Annual General Meeting on June 6, 2025, where all proposed resolutions were passed by shareholder vote. Key resolutions included the re-election of directors, re-appointment of Ernst & Young as auditors, and authorization for the board to manage share issuance and repurchase. These decisions reflect the company’s stable governance structure and strategic focus on maintaining financial and operational flexibility, potentially impacting its market positioning positively.

Sihuan Pharmaceutical’s Bireociclib Tablets Gain Approval for Advanced Breast Cancer Treatment

Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has received marketing authorization from the National Medical Products Administration for its innovative drug, Bireociclib Tablets, for two indications in HR+/HER2- advanced breast cancer. This approval marks a significant milestone as Bireociclib is the only CDK4/6 inhibitor approved in China for monotherapy in later-line treatment, showcasing the company’s strong R&D capabilities. The drug’s approval is expected to address treatment bottlenecks in breast cancer therapy, offering a promising solution for patients with limited options.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Strong Business Growth

Sihuan Pharmaceutical Holdings Group announced a share repurchase plan of up to HK$500 million, with the recent repurchase of 10 million shares at an average price of HK$0.6888 per share. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth. Sihuan has made significant progress in its medical aesthetics and pharmaceuticals segments, with substantial revenue growth and new product approvals. The company anticipates these developments will positively impact its revenue and profit, reinforcing its position in the industry.

Sihuan Pharmaceutical Announces Strategic Share Repurchase and Business Growth

Sihuan Pharmaceutical Holdings Group announced a share repurchase plan, buying back 20 million shares at an average price of HK$0.7342 per share, reflecting a strategic move to enhance shareholder value. The company has shown significant progress in its medical aesthetics and innovative pharmaceuticals sectors, with a notable revenue increase in its medical aesthetics business and the approval of 28 new products, which are expected to positively impact future revenue and profit.

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan

Sihuan Pharmaceutical Holdings Group Ltd. has announced a share repurchase plan of up to HK$500 million, reflecting its confidence in the company’s future prospects and commitment to enhancing shareholder value. This move aligns with its strategic goals, as the company continues to expand its medical aesthetics and biopharmaceutical businesses, with significant growth reported in its medical aesthetics segment and several new product approvals expected to boost revenue.